NCT04002739 (PROPHET-ACS) is a NA clinical trial of Polygraphy in ST Elevated Myocardial Infarction, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT04002739?

NCT04002739 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT04002739?

Interventions in NCT04002739: Polygraphy.

What condition does NCT04002739 study?

NCT04002739 studies ST Elevated Myocardial Infarction, Sleep-Disordered Breathing, Sleep, NSTEMI - Non-ST Segment Elevation MI.

Is NCT04002739 still recruiting?

NCT04002739 is currently status unknown. Last updated 13 August 2019.

Last reviewed 2019-08-13 · How we verify

NCT04002739: PROPHET-ACS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRedictOrs, PHEnotypes and Timing of Obstructive Sleep Apnea in Acute Coronary Syndrome

Status unknown NA Last updated 13 August 2019

What this trial tests

NA trial testing Polygraphy in ST Elevated Myocardial Infarction in 50 participants. Status unknown.

Timeline

15 June 2019

Primary endpoint
15 September 2019

15 December 2019

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	15 June 2019
Primary completion	15 September 2019
Estimated completion	15 December 2019
Sites	1 location across Italy

Drugs / interventions tested

Polygraphy

Conditions studied

ST Elevated Myocardial Infarction — all drugs for ST Elevated Myocardial Infarction →
Sleep-Disordered Breathing — all drugs for Sleep-Disordered Breathing →
Sleep — all drugs for Sleep →
NSTEMI - Non-ST Segment Elevation MI — all drugs for NSTEMI - Non-ST Segment Elevation MI →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

Adults 18 to 85, any sex, with ST Elevated Myocardial Infarction or Sleep-Disordered Breathing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obstructive Sleep Apnea (OSA) is a well-known disorder of upper airways collapse during sleep time leading to oxygen desaturation and sleep fragmentation. Despite being increasingly recognized as cardiovascular risk, the effect of OSA on clinical outcomes after Acute Coronary Syndrome (ACS) is not fully defined. Also, OSA syndrome is highly prevalent in ACS and may be related to the deterioration of cardiac function resulting in worsening of the severity of sleep apnea or the intermittent hypoxia could be cardio-protective via the ischemic preconditioning event. Serial sleep studies have shown the progressive reduction of the Apnea / Hypopnea Index (AHI) from the admission in Coronary Care Unit (CCU) to 6 weeks, 12 weeks and 6-month follow up, making necessary to re-assess the severity of OSA after discharge. Therefore, further research in this field is necessary to screen and predict those ACS patients who may experience a change in their AHI index over time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Polygraphy

Trials testing the same drug.

NCT06810479 — A Study Comparing Two Mandibular Advancement Devices in the Treatment of Sleep Apnea · NA · not yet recruiting
NCT05204004 — The Sunrise OSA Trial · NA · completed
NCT04448470 — Daytime Sleepiness in Patients With the Assessment of a Sleep-related Respiratory Disorder · unknown

Other recruiting trials for ST Elevated Myocardial Infarction

Currently open trials in the same condition.

NCT05491200 — Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients · Phase 4 · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04002739 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 13 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04002739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing